小程序掃碼下單
本網站銷售的所有產品僅用于工業應用或者科學研究等非醫療目的，不可用于人類或動物的臨床診斷或者治療，非藥用，非食用。
維多珠單抗
英文名：Vedolizumab
Cas號：943609-66-3
Cas號：943609-66-3
檢測信息查詢
| 貨號 | 規格 | 貨期 | 庫存 | 價格 | 促銷價 | 訂購 |
| 13081324921-1mg | 99.64% | 0 | ￥5800 | |||
| 13081324921-5mg | 99.64% | 0 | ￥17600 |
| 別 名 | |
| Cas號 | 943609-66-3 |
| M D L | |
| 分子式 | |
| 分子量 | |
| 產品參數 | Description
Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease. IC50 & Target Integrin[1] Storage Please store the product under the recommended conditions in the Certificate of Analysis. |
| 性狀 | Vedolizumab是一種靶向α4β7整聯蛋白 (integrin) 的人源化單克隆抗體，用來治療潰瘍性結腸炎和克羅恩病。 |
| 貯存 | References [1]. Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. [2]. Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7( |
滬公網安備 31012002003054號